Senseonics (NYSE:SENS) Now Covered by Analysts at StockNews.com

Analysts at StockNews.com assumed coverage on shares of Senseonics (NYSE:SENS) in a report issued on Saturday. The brokerage set a “sell” rating on the stock.

Separately, HC Wainwright reissued a “buy” rating and issued a $2.00 price objective on shares of Senseonics in a research report on Wednesday, August 14th.

Senseonics Trading Down 2.0 %

SENS stock opened at $0.36 on Friday. The firm has a fifty day moving average price of $0.41 and a 200 day moving average price of $0.45. Senseonics has a fifty-two week low of $0.32 and a fifty-two week high of $0.75. The firm has a market cap of $192.81 million, a PE ratio of -2.57 and a beta of 0.79. The company has a debt-to-equity ratio of 59.17, a quick ratio of 2.89 and a current ratio of 3.11.

Senseonics (NYSE:SENS) last announced its quarterly earnings results on Thursday, August 8th. The company reported ($0.03) EPS for the quarter, meeting analysts’ consensus estimates of ($0.03). Senseonics had a negative net margin of 335.15% and a negative return on equity of 299.69%. The firm had revenue of $4.87 million during the quarter, compared to the consensus estimate of $4.86 million. Sell-side analysts anticipate that Senseonics will post -0.13 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Senseonics

Several institutional investors have recently bought and sold shares of SENS. Cubist Systematic Strategies LLC lifted its stake in shares of Senseonics by 25.9% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock worth $166,000 after purchasing an additional 85,501 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Senseonics during the first quarter valued at about $162,000. Price T Rowe Associates Inc. MD lifted its position in shares of Senseonics by 16.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 367,200 shares of the company’s stock valued at $196,000 after buying an additional 51,000 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of Senseonics by 0.7% in the 1st quarter. Vanguard Group Inc. now owns 22,525,039 shares of the company’s stock valued at $11,963,000 after buying an additional 155,715 shares in the last quarter. Finally, State Board of Administration of Florida Retirement System purchased a new position in shares of Senseonics in the 1st quarter worth approximately $91,000. 12.36% of the stock is owned by hedge funds and other institutional investors.

Senseonics Company Profile

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.